• PDF / 169,419 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 108 Downloads / 157 Views

DOWNLOAD

REPORT

---

1 S

Neurotoxicity and fatal cytokine release syndrome: case report In an observational study type clinical trial (ChiCTR1800014457) of 17 paediatric patients, 1 patient [exact age and sex not stated] was described, who developed neurotoxicity and fatal cytokine release syndrome (CRS) during treatment with unspecified CAR-Tcell-therapies, cyclophosphamide and fludarabine for B-cell non-Hodgkin’s lymphoma (NHL). The patient, who had NHL, received treatment with cyclophosphamide 250 mg/m2/day on days -5, -4 and -3, fludarabine 30 mg/ m2/day and a single dose infusion of unspecified CAR-T-cell therapies (CAR-T cells) on day 0. However, the patient developed neurotoxicity and severe CRS (respiratory failure, shock, capillary leak syndrome, high fever, cardiopulmonary arrest and severe pleural effusion) besides disease progression. At day 6, the patient died due to the disease progression and CRS. Zhang W, et al. Early response observed in pediatric patients with refractory/relapsed b-cell non-hodgkin lymphoma treated with sequential chimeric antigen receptor T cells. 803447237 Blood 134 (Suppl. 1): 1945, Nov 2019. Available from: URL: http://doi.org/10.1182/blood-2019-125753 [abstract]

0114-9954/20/1787-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 18 Jan 2020 No. 1787